A cooperative process to reach mutually acceptable solutions that respects all stakeholders, improves our common understanding and establishes sustainable mutual trust

PRELIMINARY PROGRAMME

DAY 1: Wednesday, 22 February 2017

09.00 to 18.30

09.00 – 13.00	***INTRODUCTION & OPENING PLENARY*** ***EXPRESSION OF STAKEHOLDER INTERESTS*** *Live video streaming* *Co-Chairs: Charles Barker, PrimeMover Associates, USA (confirmed) & Peter O'Donnell, Politico, Belgium (confirmed)*
09.00 - 09.15	**Welcome & Introduction** Charles Barker, PrimeMover Associates, USA (confirmed)
09.15 – 09.30	**Setting the scene** Yann Le Cam, Chief Executive Officer, EURORDIS (confirmed)
09.30 – 09.40	**Patient case study** Speaker to be named
09.40 – 09.55	**The role of the European Commission on improving access to rare disease therapies** Xavier Prats Monné, Director General, Directorate-General for Health and Food Safety, European Commission (confirmed)
09.55 – 11.25	**PANEL discussion:** moderated by Co-Chairs **Industry decision-makers** What have been the most important changes in the last year? What are the challenges? What are the options moving forward? How do we work together to improve this? **Panellists (confirmed):** Michael Goettler, Global President, Rare Disease Business, Pfizer Tuomo Pätsi, President EMEA, Celgene Additional panellists and questioners to be named Q&A from on-site and online audiences
11.25 – 11.40	*Coffee break*
11.40 – 13.00	**PANEL discussion:** moderated by Co-Chairs **Policy decision-makers** What have been the most important changes in the last year? What are the challenges? What are the options moving forward? How do we work together to improve this? **Panellists (confirmed):** Diane Kleinermans, representative of the Minister of Public Health, Belgium Additional panellists and questioners to be named Q&A from on-site and online audiences

13.00 – 14.00	*LUNCH (Salon Adolphe Max)*
14.00 – 18.30	***PLENARY***
14.00 – 14.10	**Patient case study** Speaker to be named
14.10 – 14.25	**Collaborating for success** Karen Facey, HTAi, UK (confirmed)
14.25 – 14.55	**Current state of the art in multi-stakeholder collaborative processes** Early dialogue initiatives & expedited regulatory pathways **Speakers (confirmed):** Hans-Georg Eichler, Senior Medical Officer, EMA Simon Day, Chair, IRDiRC Small-Patients Clinical Trial Task Force, Director, Clinical Trials Consulting & Training Limited, UK Additional speakers to be named
15.10 – 16.15	**Multi-stakeholder panel discussion: success factors for collaboration in relation to access** **Panellists (confirmed):** Hans-Georg Eichler, Senior Medical Officer, EMA Ri de Ridder, Director General, RIZIV/INAMI, Belgium Additional panellists to be named Q&A from on-site and online audiences
16.15 – 16.30	*Coffee break*
16.30 – 18.00	**From diverging positions to common interests** **A collaborative conversation for transformative operational solutions serving the interests of each stakeholder** Moderator: Charles Barker, PrimeMover Associates, USA (confirmed)
18.00 – 18.30	**Conclusions from Day 1** Peter O'Donnell, Politico, Belgium (confirmed)
18.30	End of Day 1

DAY 2: Thursday, 23 February 2017

08.00 – 18.00

08.00 – 09.00	***PLENARY*** ***Co-Chairs: to be named***
08.00 – 08.15	**Trajectory from Day 1 & Aims of Day 2** Session Chairs

08.15 – 08.25	**Patient case study** Speaker to be named		
08.25 – 08.45	**Introduction to breakout sessions** Moderators of breakouts		
09.00 – 11.00	***BREAKOUT SESSIONS* – Emerging options**		
	Breakout 1: Quality Data Generation	**Breakout 2: Value for money across Europe**	**Breakout 3: Pricing**
	Pan-European disease & product registries to address needs of all stakeholders Moderator & Rapporteur to be named	**Common principles for value determination and assessment** Moderator: Lieven Annemans, Ghent University, Belgium (tbc) Rapporteur: to be named	**Innovative performance based outcome agreements** Moderator & Rapporteur to be named
11.00 – 11.15	*Coffee break*		
11.15 – 12.30	***PLENARY*** ***Co-Chairs: to be named***		
11.15 – 12.30	**Feedback and discussion from breakout sessions** Co-Chairs & rapporteurs from breakouts		
12.30 – 13.30	*LUNCH (Salon Adolphe Max)*		
13.30 – 15.30	***BREAKOUT SESSIONS* - New options**		
	Breakout 4: Quality Data Generation	**Breakout 5: Value for money across Europe**	**Breakout 6: Pricing**
	How European Reference Networks (ERNs) could become part of the solution / enablers of quality data generation? Moderator & Rapporteur to be named	**Proposals for coordination of HTA across Europe: implications for rare diseases** Moderator to be named Rapporteur: Julia Chamova, Director, Global Networks (EMEA), ISPOR, Sweden (confirmed)	**Potential for European collaboration among payers and companies** Moderator: Ri de Ridder, Director General, RIZIV/INAMI, Belgium (confirmed) Rapporteur to be named
15.30 – 15.45	*Coffee break*		
15.45 – 18.00	***PLENARY*** ***Co-Chairs: to be named***		
15.45 – 16.45	**Feedback and discussion from breakout sessions** Co-Chairs & rapporteurs from breakouts		
16.45 – 17.45	**Panel discussion: Paving the way to a fair, inclusive and on-going multi-stakeholder approach with the potential to generate sustainable, affordable and actionable improvements in patient access to rare disease therapies** Panellists to be named		

	Q&A
17.45 – 18.00	**Conclusions & closing remarks** Yann Le Cam, Chief Executive Officer, EURORDIS
18.00	End of Day 2 – End of symposium